Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 129.46 USD 0.14% Market Closed
Market Cap: $8.4B

Operating Margin

-31%
Current
Improving
by 128.9%
vs 3-y average of -159.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-31%
=
Operating Income
$-174.3m
/
Revenue
$562.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-31%
=
Operating Income
$-174.3m
/
Revenue
$562.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Blueprint Medicines Corp
NASDAQ:BPMC
8.4B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 79% of companies in the United States of America
Percentile
21th
Based on 14 112 companies
21th percentile
-31%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Blueprint Medicines Corp
Glance View

In the demanding world of biotechnology, Blueprint Medicines Corp stands out as an influential player, steering the course of precision therapy through innovation. Founded by a team of forward-thinking scientists, the company is deeply entrenched in the pursuit of novel treatments targeting rare genetic diseases and cancers driven by specific genomic alterations. Leveraging its proprietary compound library and a research-centric approach, Blueprint Medicines develops small-molecule kinase inhibitors designed to selectively modulate growth and survival signals in cells. The company’s strategic focus on genomically defined indications allows it to address unmet medical needs, thereby creating substantial value through focused research and rapid clinical advancements. The financial backbone of Blueprint Medicines is built upon a well-rounded strategy encompassing both in-house drug development and strategic collaborations. As the company shepherds its proprietary drugs through the rigorous phases of clinical trials, it also engages in valuable partnerships with pharmaceutical giants to bolster its research capabilities and market reach. With approval and commercialization of therapies like Ayvakit for certain forms of gastrointestinal stromal tumors, Blueprint Medicines generates substantial revenue. These gains are further compounded by milestone payments and royalties from collaborations, all while maintaining a robust pipeline to ensure continued innovation and future income streams. In this way, Blueprint marries scientific rigor with strategic acumen, carving out a sustainable and impactful presence in the biopharmaceutical landscape.

BPMC Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-31%
=
Operating Income
$-174.3m
/
Revenue
$562.1m
What is Blueprint Medicines Corp's current Operating Margin?

The current Operating Margin for Blueprint Medicines Corp is -31%, which is above its 3-year median of -159.9%.

How has Operating Margin changed over time?

Over the last 3 years, Blueprint Medicines Corp’s Operating Margin has increased from -292.7% to -31%. During this period, it reached a low of -302.3% on Jun 30, 2022 and a high of -31% on May 1, 2025.

Back to Top